Pfizer (PFE)
24.61
+0.31 (1.28%)
NYSE · Last Trade: Nov 5th, 9:36 PM EST
The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in turn, significantly bolstered the US Dollar, pushing it to multi-month highs against a basket of major currencies. The immediate implication for
Via MarketMinute · November 5, 2025
The financial markets, still reeling from a tumultuous period marked by significant downturns, are now grappling with an uneasy attempt at consolidation. As of November 5, 2025, investors are witnessing a landscape fundamentally altered by a series of sharp slides, most notably the tariff-induced crash of April 2025 and a
Via MarketMinute · November 5, 2025
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugsstocktwits.com
Via Stocktwits · November 4, 2025
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo Nordisk (NYSE: NVO), a pioneer in the space with its blockbuster drugs Wegovy and Ozempic, has experienced a tumultuous year, seeing
Via MarketMinute · November 5, 2025
The United States finds itself in an unprecedented economic fog as a prolonged government shutdown, now stretching well into its second month, has brought the flow of critical official data to a grinding halt. With federal agencies responsible for collecting and disseminating vital economic indicators largely shuttered, policymakers, businesses, and
Via MarketMinute · November 5, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Wednesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · November 5, 2025
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD) has successfully leveraged AI to design antibodies from scratch, achieving unprecedented atomic precision. This groundbreaking development, primarily driven by a sophisticated generative AI model [...]
Via TokenRing AI · November 5, 2025
Washington D.C., November 5, 2025 – The United States is grappling with an unprecedented fiscal crisis, as an ongoing government shutdown, now in its 36th day, has officially become the longest in the nation's history. This prolonged political impasse, rooted in fierce partisan disagreements over federal spending and policy riders,
Via MarketMinute · November 5, 2025
Three factors took Viking's shares higher in the month.
Via The Motley Fool · November 5, 2025
These supercharged income stocks have the necessary catalysts to pad the pocketbooks of patient investors.
Via The Motley Fool · November 5, 2025
Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.
Via Stocktwits · November 5, 2025
Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.
Via StockStory · November 5, 2025
The financial world is holding its breath as the release of the upcoming U.S. Purchasing Managers' Index (PMI) data draws near. This crucial economic indicator is not merely a snapshot of business activity; it's a powerful barometer of the nation's economic health, capable of sending significant ripple effects through
Via MarketMinute · November 4, 2025
As of November 4, 2025, the global financial markets are witnessing a significant shift, with a rallying US dollar and a retreating stock market exerting considerable downward pressure on gold and silver prices. This confluence of macroeconomic factors, primarily driven by a hawkish outlook on interest rates, is creating a
Via MarketMinute · November 4, 2025
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
Via TokenRing AI · November 4, 2025
Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.
Via Benzinga · November 4, 2025
Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight.
Via Benzinga · November 4, 2025
Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · November 4, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.
Via Chartmill · November 4, 2025
Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs.
Via Benzinga · November 4, 2025
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date rallies.
Via Benzinga · November 4, 2025
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Tuesday's session.
Via Chartmill · November 4, 2025
Pfizer (PFE) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 4, 2025
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.
Via Investor's Business Daily · November 4, 2025
